Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering (IMRX) recorded quarterly Capital Expenditures of $79930.0 in Q1 2026, down 35.49% quarter-over-quarter from $123910.0 in Q4 2025, and up 793.57% on a YoY basis from $8945.0 in Q1 2025.
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Immuneering's Capital Expenditures history runs 7 years deep, the most recent figure standing at $79930.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 793.57% year-over-year to $79930.0; the TTM figure through Mar 2026 stood at $213211.0 (up 278.42% YoY), while the FY2025 annual figure was $142226.0, up 67.57% from the prior year.
- Capital Expenditures was $79930.0 for Q1 2026 at Immuneering, down from $123910.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $393134.0 in Q3 2022 to a low of $2116.0 in Q2 2025.
- Historically, Capital Expenditures has averaged $81897.6 across 5 years, with a median of $57149.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 3364.96% in 2022, then slumped 94.53% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $69302.0 in 2022, then jumped by 146.63% to $170918.0 in 2023, then plunged by 94.53% to $9356.0 in 2024, then surged by 1224.39% to $123910.0 in 2025, then plunged by 35.49% to $79930.0 in 2026.
- The last three Capital Expenditures figures came in at $79930.0 (Q1 2026), $123910.0 (Q4 2025), and $7255.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 79,930.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,930.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Mar 31, 2024 | 37,478.00 |
| Dec 31, 2023 | 170,918.00 |
| Dec 31, 2023 | 170,918.00 |